Omeros Reports Strong Q4 Results with Novo Nordisk Deal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy OMER?
Source: stocktwits
- Significant Transaction Gains: Omeros reported a net gain of $237.6 million in Q4 due to the zaltenibart transaction with Novo Nordisk, which is valued at up to $2.1 billion, marking a major advancement in the biopharmaceutical sector.
- FDA Approval for New Drug: Yartemlea received FDA approval in December for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy, with commercial sales starting in January, expected to significantly boost revenue and market share.
- Positive Market Reaction: Omeros shares rose 5% in after-hours trading, reflecting investor optimism regarding the partnership with Novo Nordisk and other drug prospects, with a 28% increase in stock price over the past year indicating growing market confidence.
- Optimistic Future Outlook: The company anticipates approval from the European Medicines Agency by mid-2026, with the CEO stating that the partnership with Novo will provide ongoing operating capital, supporting the development of future product portfolios and aiming for positive cash flow by 2027.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OMER?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OMER
Wall Street analysts forecast OMER stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 9.810
Low
36.00
Averages
43.67
High
55.00
Current: 9.810
Low
36.00
Averages
43.67
High
55.00
About OMER
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The Company's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The Company also has preclinical programs, including an oncology platform for the development of novel therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Omeros Scheduled to Announce Q4 Earnings on March 30
- Earnings Announcement Schedule: Omeros is set to release its Q4 earnings on March 30 after market close, with a consensus EPS estimate of $0.36, reflecting a substantial year-over-year growth of 166.7%, indicating significant improvement in profitability.
- Earnings Performance Analysis: Over the past year, Omeros has beaten EPS estimates 75% of the time, although it has not exceeded revenue estimates, suggesting that its market sales strategy may need optimization to enhance revenue performance.
- FDA Approval and Market Plans: Omeros is discussing its FDA approval and commercialization plans for YARTEMLEA in TA-TMA treatment, which could provide new revenue streams and strengthen its competitive position in the market.
- Impact of First Commercial Sales: The initiation of Omeros's first commercial sales in transplant therapy is expected to generate positive market responses, further solidifying its position in the biopharmaceutical industry.
See More
Omeros Reports Strong Q4 Results with Novo Nordisk Deal
- Significant Transaction Gains: Omeros reported a net gain of $237.6 million in Q4 due to the zaltenibart transaction with Novo Nordisk, which is valued at up to $2.1 billion, marking a major advancement in the biopharmaceutical sector.
- FDA Approval for New Drug: Yartemlea received FDA approval in December for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy, with commercial sales starting in January, expected to significantly boost revenue and market share.
- Positive Market Reaction: Omeros shares rose 5% in after-hours trading, reflecting investor optimism regarding the partnership with Novo Nordisk and other drug prospects, with a 28% increase in stock price over the past year indicating growing market confidence.
- Optimistic Future Outlook: The company anticipates approval from the European Medicines Agency by mid-2026, with the CEO stating that the partnership with Novo will provide ongoing operating capital, supporting the development of future product portfolios and aiming for positive cash flow by 2027.
See More
Omeros Reports Q4 Earnings Exceeding Expectations
- Earnings Beat: Omeros reported a Q4 non-GAAP EPS of $3.14, surpassing expectations by $2.78, indicating a significant improvement in profitability that may attract more investor interest.
- Strong Cash Position: As of December 31, 2025, Omeros had $171.8 million in cash and short-term investments, ensuring ample funding for future R&D and market expansion, thereby enhancing financial stability.
- Debt Reduction: Omeros' total debt stood at $87.9 million as of December 31, 2025, reflecting a $77.1 million or 47% decrease from $164.9 million in 2024, showcasing significant progress in financial management and reducing financial risk.
- Positive Market Outlook: Progress in FDA approval and commercialization plans for Yartemlea, along with successful first commercial sales, is expected to generate new revenue streams and further solidify Omeros' position in the transplant therapy market.
See More
Multiple Companies Set to Report Earnings
- Nike Earnings Forecast: Nike (NKE) is expected to report an earnings per share of $0.29 for the quarter ending February 28, 2026, representing a 46.30% decrease compared to the same quarter last year, indicating increased competitive pressure despite beating expectations consistently over the past year.
- PVH Earnings Outlook: PVH is forecasting an earnings per share of $3.30 for the quarter ending January 31, 2026, reflecting a modest 0.92% increase year-over-year, demonstrating its stable market position as it has consistently exceeded market expectations in the past year.
- RH Earnings Growth: RH anticipates an earnings per share of $2.21 for the quarter ending January 31, 2026, marking a significant 39.87% year-over-year increase, showcasing strong business growth potential that may attract more investor interest.
- nCino Earnings Prediction: nCino expects an earnings per share of $0.06 for the quarter ending January 31, 2026, representing a remarkable 250.00% increase compared to the same quarter last year, which could help restore market confidence after previous underperformance.
See More
Omeros to Host Industry Session at EBMT Annual Meeting
- Industry Session Announcement: Omeros Corporation will host an industry session on March 22, 2026, in Madrid, Spain, titled 'Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy,' attracting professionals from the global blood and marrow transplantation field.
- Key Speakers: The session will be co-chaired by Rafael Duarte and Mohamad Mohty, featuring speakers Miguel-Angel Perales from Memorial Sloan Kettering Cancer Center and Michelle L. Schoettler from Children's Healthcare of Atlanta, showcasing Omeros' influence in the field.
- Product Overview: Omeros' lead product YARTEMLEA® is FDA-approved for treating TA-TMA in adults and children, currently available in the U.S. market, indicating significant market potential in therapeutic applications.
- R&D Progress: Omeros' long-acting MASP-2 inhibitor OMS1029 has successfully completed Phase 1 clinical trials, further solidifying its research capabilities in complement-mediated disease treatments.
See More
Omeros Corporation Begins First Shipments of Yartemlea Therapy
- FDA Approval: Omeros Corporation received FDA approval in December to market Yartemlea for patients aged two and older, showcasing the company's innovative capabilities in the biotech sector.
- First Shipments: The company began its first commercial shipments of Yartemlea last week, fulfilling initial orders from multiple transplant centers, marking a critical step in product market entry and expected to significantly boost revenue.
- Therapeutic Impact: Yartemlea targets TA-TMA, which has a mortality rate exceeding 90% in severe cases, thus its launch provides a new treatment option for high-risk patients, potentially improving survival rates and quality of life.
- Market Demand: Patients currently undergoing Yartemlea therapy include adults and children who have failed prior off-label C5-inhibitor regimens in both inpatient and outpatient settings, indicating the drug's broad applicability and market potential.
See More
Omeros Scheduled to Announce Q4 Earnings on March 30
- Earnings Announcement Schedule: Omeros is set to release its Q4 earnings on March 30 after market close, with a consensus EPS estimate of $0.36, reflecting a substantial year-over-year growth of 166.7%, indicating significant improvement in profitability.
- Earnings Performance Analysis: Over the past year, Omeros has beaten EPS estimates 75% of the time, although it has not exceeded revenue estimates, suggesting that its market sales strategy may need optimization to enhance revenue performance.
- FDA Approval and Market Plans: Omeros is discussing its FDA approval and commercialization plans for YARTEMLEA in TA-TMA treatment, which could provide new revenue streams and strengthen its competitive position in the market.
- Impact of First Commercial Sales: The initiation of Omeros's first commercial sales in transplant therapy is expected to generate positive market responses, further solidifying its position in the biopharmaceutical industry.
See More
Omeros Reports Strong Q4 Results with Novo Nordisk Deal
- Significant Transaction Gains: Omeros reported a net gain of $237.6 million in Q4 due to the zaltenibart transaction with Novo Nordisk, which is valued at up to $2.1 billion, marking a major advancement in the biopharmaceutical sector.
- FDA Approval for New Drug: Yartemlea received FDA approval in December for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy, with commercial sales starting in January, expected to significantly boost revenue and market share.
- Positive Market Reaction: Omeros shares rose 5% in after-hours trading, reflecting investor optimism regarding the partnership with Novo Nordisk and other drug prospects, with a 28% increase in stock price over the past year indicating growing market confidence.
- Optimistic Future Outlook: The company anticipates approval from the European Medicines Agency by mid-2026, with the CEO stating that the partnership with Novo will provide ongoing operating capital, supporting the development of future product portfolios and aiming for positive cash flow by 2027.
See More
Omeros Reports Q4 Earnings Exceeding Expectations
- Earnings Beat: Omeros reported a Q4 non-GAAP EPS of $3.14, surpassing expectations by $2.78, indicating a significant improvement in profitability that may attract more investor interest.
- Strong Cash Position: As of December 31, 2025, Omeros had $171.8 million in cash and short-term investments, ensuring ample funding for future R&D and market expansion, thereby enhancing financial stability.
- Debt Reduction: Omeros' total debt stood at $87.9 million as of December 31, 2025, reflecting a $77.1 million or 47% decrease from $164.9 million in 2024, showcasing significant progress in financial management and reducing financial risk.
- Positive Market Outlook: Progress in FDA approval and commercialization plans for Yartemlea, along with successful first commercial sales, is expected to generate new revenue streams and further solidify Omeros' position in the transplant therapy market.
See More
Multiple Companies Set to Report Earnings
- Nike Earnings Forecast: Nike (NKE) is expected to report an earnings per share of $0.29 for the quarter ending February 28, 2026, representing a 46.30% decrease compared to the same quarter last year, indicating increased competitive pressure despite beating expectations consistently over the past year.
- PVH Earnings Outlook: PVH is forecasting an earnings per share of $3.30 for the quarter ending January 31, 2026, reflecting a modest 0.92% increase year-over-year, demonstrating its stable market position as it has consistently exceeded market expectations in the past year.
- RH Earnings Growth: RH anticipates an earnings per share of $2.21 for the quarter ending January 31, 2026, marking a significant 39.87% year-over-year increase, showcasing strong business growth potential that may attract more investor interest.
- nCino Earnings Prediction: nCino expects an earnings per share of $0.06 for the quarter ending January 31, 2026, representing a remarkable 250.00% increase compared to the same quarter last year, which could help restore market confidence after previous underperformance.
See More
Omeros to Host Industry Session at EBMT Annual Meeting
- Industry Session Announcement: Omeros Corporation will host an industry session on March 22, 2026, in Madrid, Spain, titled 'Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy,' attracting professionals from the global blood and marrow transplantation field.
- Key Speakers: The session will be co-chaired by Rafael Duarte and Mohamad Mohty, featuring speakers Miguel-Angel Perales from Memorial Sloan Kettering Cancer Center and Michelle L. Schoettler from Children's Healthcare of Atlanta, showcasing Omeros' influence in the field.
- Product Overview: Omeros' lead product YARTEMLEA® is FDA-approved for treating TA-TMA in adults and children, currently available in the U.S. market, indicating significant market potential in therapeutic applications.
- R&D Progress: Omeros' long-acting MASP-2 inhibitor OMS1029 has successfully completed Phase 1 clinical trials, further solidifying its research capabilities in complement-mediated disease treatments.
See More
Omeros Corporation Begins First Shipments of Yartemlea Therapy
- FDA Approval: Omeros Corporation received FDA approval in December to market Yartemlea for patients aged two and older, showcasing the company's innovative capabilities in the biotech sector.
- First Shipments: The company began its first commercial shipments of Yartemlea last week, fulfilling initial orders from multiple transplant centers, marking a critical step in product market entry and expected to significantly boost revenue.
- Therapeutic Impact: Yartemlea targets TA-TMA, which has a mortality rate exceeding 90% in severe cases, thus its launch provides a new treatment option for high-risk patients, potentially improving survival rates and quality of life.
- Market Demand: Patients currently undergoing Yartemlea therapy include adults and children who have failed prior off-label C5-inhibitor regimens in both inpatient and outpatient settings, indicating the drug's broad applicability and market potential.
See More
